Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors

Volume: 50, Issue: 8, Pages: 812 - 819
Published: Aug 1, 2018
Abstract
Adalimumab is the second tumour necrosis factor antagonist (anti-TNF) adopted for the treatment of ulcerative colitis. Clinical data from naïve patients are scarce.Examine the response to adalimumab in TNF-antagonist-naïve patients.This multicentre, observational, prospective study was conducted using a cohort of consecutive patients with ulcerative colitis. Clinical remission, mucosal healing and deep remission were examined employing the Mayo...
Paper Details
Title
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors
Published Date
Aug 1, 2018
Volume
50
Issue
8
Pages
812 - 819
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.